Molecular Partners AG (NAS:MOLN)
$ 5.3 -0.01 (-0.19%) Market Cap: 195.73 Mil Enterprise Value: 38.95 Mil PE Ratio: 0 PB Ratio: 1.10 GF Score: 62/100

Molecular Partners AG at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 12:30PM GMT
Richard Vosser
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, and good afternoon. Welcome to the fourth day of the JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan. And it's my great pleasure to introduce the CEO of Molecular Partners, Patrick Amstutz, for this presentation.

Before I hand over to Patrick, just a few remarks on Q&A. You can access the Q&A section of the website at any time to ask your question, and then I will read that out for you at the appropriate time during the Q&A portion of this presentation.

With that, I'd like to say a great welcome to Patrick. Patrick, over to you.

Patrick Amstutz
Molecular Partners AG - Co-Founder, CEO, Member of Management Board & Director

Thanks, Richard, and thanks for the introduction. And I hear that I don't control the slides, so you do that. So I will also refer to which slide I'm on that you can push the slides to where I am presenting.

I think, obviously, this is a very special JPMorgan. And in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot